Abstracts tagged "Biomarkers"

Abstract Number: 869 • 2016 ACR/ARHP Annual Meeting
Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Abraham Rutgers¹, Suzanne Arends¹, Annemieke M.H. Boots¹ and Elisabeth Brouwer³, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) is the most frequent inflammatory disorder in persons older than 50 years of age. Biomarkers like ESR and CRP may be…
Abstract Number: 1638 • 2016 ACR/ARHP Annual Meeting
Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients
Boel Brynedal¹, Helga Westerlind², Lasse Folkersen^3,4, Leonid Padyukov⁵, Nancy Vivar⁵, Anca I Catrina⁶, Lars Klareskog⁵ and Louise Berg⁵, ¹Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ²Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Methotrexate (MTX) is the first line treatment for Rheumatoid Arthritis (RA) in Sweden, but one third of patients do not experience satisfying treatment response.…
Abstract Number: 2135 • 2016 ACR/ARHP Annual Meeting
Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation
Anne C. Bay-Jensen¹, Steven B. Abramson², Jonathan Samuels³, Inger Byrjalsen⁴, Svetlana Krasnokutsky Samuels⁵, Tina Manon-Jensen⁶, Morten Asser Karsdal¹ and Mukundan Attur⁷, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, ³Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, NY, ⁴Nordic Bioscience, Clinical Development, Herlev, Denmark, ⁵Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁷Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease characterized by pain and tissue destruction, in some cases concomitant with inflammation. The link between pain and tissue destruction…
Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Arata Nakajima¹, Keiichiro Yamamoto² and Koichi Nakagawa³, ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Orthopedics, Toho University Sakura Medical Center, Sakura, Japan, ³Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Yahui Grace Chiu¹, Edward Schwarz², Richard Bell³, Dongge Li⁴, Nelson Huertas⁴, Cristy Bell⁵, Sharon Moorehead⁵, Debbie Campbell⁵, Changyong Feng⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Statistics, University of Rochester, Rochester, NY, ⁷Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…
Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen², Jeppe Andersen³, Christian S. Thudium⁴, Bente J. Riis², Claus Christiansen², Hans Guehring⁵, Martin Michaelis⁵, Christoph Ladel⁵ and Morten Asser Karsdal⁶, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Merck KGaA, Darmstadt, Germany, ⁶Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…
Abstract Number: 914 • 2016 ACR/ARHP Annual Meeting
Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Seunghee Hong¹, Romain Banchereau¹, Marta M. Guerra², Jane E. Salmon^3,4 and Virginia Pascual¹, ¹Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ²Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: SLE is a systemic autoimmune disease that predominantly affects women in reproductive years. SLE pregnancies result in higher rates of adverse outcomes compared with…
Abstract Number: 1652 • 2016 ACR/ARHP Annual Meeting
Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Natasja Stæhr Gudman¹, Pernille Juhl², Christian S. Thudium³, Anne Sofie Siebuhr⁴, Inger Byrjalsen⁵, Morten Asser Karsdal⁴ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which…
Abstract Number: 2136 • 2016 ACR/ARHP Annual Meeting
CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model
Nisha Sambamurthy^1,2, Vu Nguyen^1,2, Ryan Smalley^2,3, George R. Dodge^3,4 and Carla R. Scanzello^1,2,3, ¹Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Translational Musculoskeletal Research Center, CMC Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Orthopedic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Research, CMC Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: CD14, though expressed by multiple cell types, is highly expressed by monocytes and macrophages. It forms a complex with Toll-like receptors (TLRs), particularly TLR-2…
Abstract Number: 2619 • 2016 ACR/ARHP Annual Meeting
Sustained Suppression of Peripheral Biomarkers By Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in the Phase IIb Earth Explorer 2 Clinical Trial
Xiang Guo¹, Shiliang Wang¹, Anne C. Bay-Jensen², Morten Asser Karsdal², A Godwood³, Marius Albulescu³, D Close³, Patricia C. Ryan¹, Lorin Roskos⁴ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Rheumatology, Nordic Bioscience, Herlev, Denmark, ³MedImmune, Cambridge, United Kingdom, ⁴MedImmune, LLC, Mountain View, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) patients by anti-tumour necrosis factors (anti-TNFs), such as golimumab, has improved patient outcomes. However, unmet therapeutic needs exist for…
Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting
Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Duncan Porter¹, C. S. Goodyear², J. S. Nijjar¹, Martina Messow³, Stefan Siebert¹, Manikhandan Mudaliar⁴ and Iain B. McInnes⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Polyomics Facility, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain
Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…
Abstract Number: 380 • 2016 ACR/ARHP Annual Meeting
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
AnneMarie Brescia¹, Megan Simonds², Suzanne McCahan³, Tim Bunnell³, Kathleen E. Sullivan⁴ and Carlos D. Rosé¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours, Nemours Biomedical Research, Wilmington, DE, ³Nemours Biomedical Research, Wilmington, DE, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…
Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Gaurav Gulati¹, Michael Bennett², Khalid Abulaban^3,4, Qing Ma⁵, Marisa S. Klein-Gitelman⁶, Kelly A. Rouster-Stevens⁷, Christopher Haffner⁵, Kasha Wiley⁸, Stacy P. Ardoin⁹, Jun Ying¹⁰, Prasad Devarajan¹¹ and Hermine I. Brunner⁸, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Helen DeVos Children's Hospital, Grand Rapids, MI, ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ¹⁰Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…
Abstract Number: 1656 • 2016 ACR/ARHP Annual Meeting
Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Yahui Grace Chiu¹, Edward Schwarz², Dongge Li³, Nelson Huertas³, Cristy Bell⁴, Debbie Campbell⁴ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data…
Abstract Number: 2291 • 2016 ACR/ARHP Annual Meeting
Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease
John FitzGerald¹, Benjamin D. Levine², Jennifer Raymond³ and Maureen A. McMahon¹, ¹Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gout and hyperuricemia have been associated with cardiovascular disease. Studies have documented the impact of serum urate levels on hypertension and that increased urate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].